Ross Camidge, MD, PhD, of the University of Colorado, Denver, CO, discusses single target therapies in thoracic oncology and beyond at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. He speaks about ROR-gamma, a master controller drug with the potential to revolutionize the treatment landscape.
Master controller drugs: ROR-gamma agonists to boost checkpoint inhibitor response
